| 產(chǎn)品描述： | CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes |
| 靶點(diǎn)： |
IC50: 1.5 μM (Rho-pathway selective serum response element-luciferase reporter);LRRK2;Rho;Ras |
| 體內(nèi)研究： |
CCG-1423 (0.15 mg/kg; i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice |
| 參考文獻(xiàn)： |
1. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72. 2. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. 3. Evelyn CR, et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007 Aug;6(8):2249-60. |
| 溶解性： |
DMSO : 100 mg/mL (219.90 mM; ultrasonic and warming and heat to 60°C) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.199 ml |
10.995 ml |
21.99 ml |
| 5 mM |
0.44 ml |
2.199 ml |
4.398 ml |
| 10 mM |
0.22 ml |
1.1 ml |
2.199 ml |
| 50 mM |
0.044 ml |
0.22 ml |
0.44 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營許可證（不帶存儲(chǔ)）
營業(yè)執(zhí)照(三證合一)
北京